Awakn Life Sciences has signed its first Licensing Partnership agreement in Europe with a healthcare consortium.
Portugal has a population of 10 million people and, unfortunately, the country has a relatively high lifetime prevalence of mental health conditions of around 20% to 30%.
Under the new agreement in the country, Awakn will provide its Portuguese partner with an exclusive licence for use of its clinical protocols for the treatment of Alcohol Use Disorder (AUD), anxiety, depression, eating disorders and PTSD in Portugal for a period of 10 years.
The agreement will support the Portuguese partner’s strategy to launch a new chain of medical-psychedelic clinics in Portugal, with the first location in Lisbon.
Anthony Tennyson, Awakn CEO commented “We are very pleased to expand our Licencing Partnership business by geography, into Portugal, and by scope into anxiety, depression, eating disorders, and PTSD.
“We are also delighted to work with our new partners in Portugal who are deeply experienced in, and knowledgeable of, the Portuguese mental health treatment and wellness sectors.
“With Awakn being the first chain of psychedelic clinics in Europe we have a wealth of knowledge to help accelerate the development and execution of their strategy.
“Importantly, this partnership will allow many people in Portugal to access new more effective treatment options which are not currently available.”
Awakn, which currently has ketamine clinics in the UK, including London and Bristol, as well as in Norway, has also stated that it will be training the Portuguese partner’s clinicians in the delivery of these protocols and will provide ongoing strategic, operational, risk management and marketing support.
